Mobile

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001161-14

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objective of study CAMMS323 is to compare the safety and efficacy of 2 annual cycles of IV alemtuzumab to 3-times weekly SC administration of interferon beta-1a.

Critère d'inclusion

  • Relapsing-Remitting Multiple Sclerosis

Liens